Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Valganciclovir (VGC), an oral prodrug of ganciclovir (GCV), has been shown to clear cytomegalovirus (CMV) viremia in preemptive treatment of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), apparently without significant toxicity. Since VGC obviates hospitalization, it i...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkam, Corinna, Kamal, Haytham, Dammann, Elke, Diedrich, Helmut, Buchholz, Stefanie, Eder, Matthias, Krauter, Jürgen, Ganser, Arnold, Stadler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518946/
https://www.ncbi.nlm.nih.gov/pubmed/23243512
http://dx.doi.org/10.1155/2012/874601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518946/
https://www.ncbi.nlm.nih.gov/pubmed/23243512
http://dx.doi.org/10.1155/2012/874601

Ejemplares similares